Dr. Rogers trained in four medical specialties and was a Professor and Chair at Johns Hopkins at age 37. The author of well over 100 papers and Editor of 12 books, he is a member of the National Academy of Medicine, is a former Fulbright, and former Chair of the Reagan-Udall Foundation, the U.S. Congress public advisory group on the FDA.
Dr. Rogers got an MBA from Wharton and subsequently became CEO of Duke Hospital and Health Network before joining the NYSE company that sequenced the human genome before moving into medical venture capital.
Before founding Gibson Oncology, Dr. Rogers served as founder, Chairman, and CEO of a number of companies including Innovative Drug Delivery Systems, a pharmaceutical development company with three pain-related drugs which went public and was acquired for approximately $230 million. He was founder and Chairman of Aptamera, an oncologic pharmaceutical development company that was acquired by a London public company. He was founder and Chairman of Cardiome, a NASDAQ listed cardiac arrhythmia company that reached an $800 million-dollar market while Dr. Rogers was Chair. He also was Executive Chair of the company that developed Arsenic Trioxide as a cure for Acute Promyelocytic Leukemia which, after FDA approval, was subsequently sold to a large pharma company for $100 million
Dr. Rogers and his wife, an academician, and entrepreneur in her own right, often work together. They have two children, five grandchildren, and support educational opportunities for children with limited resources.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.